We have developed a straightforward and efficient method of introducing radiopacity into Polyvinyl alcohol (PVA)-2-Acrylamido-2-methylpropane sulfonic acid (AMPS) hydrogel beads (DC Bead™) that are currently used in the clinic to treat liver malignancies. Coupling of 2,3,5-triiodobenzaldehyde to the PVA backbone of pre-formed beads yields a uniformly distributed level of iodine attached throughout the bead structure (~150 mg/mL) which is sufficient to be imaged under standard fluoroscopy and computed tomography (CT) imaging modalities used in treatment procedures (DC Bead LUMI™). Despite the chemical modification increasing the density of the beads to~1.3 g/cm 3 and the compressive modulus by two orders of magnitude, they remain easily suspended, handled and administered through standard microcatheters. As the core chemistry of DC Bead LUMI™ is the same as DC Bead™, it interacts with drugs using ion-exchange between sulfonic acid groups on the polymer and the positively charged amine groups of the drugs. Both doxorubicin (Dox) and irinotecan (Iri) elution kinetics for all bead sizes evaluated were within the parameters already investigated within the clinic for DC Bead™. Drug loading did not affect the radiopacity and there was a direct relationship between bead attenuation and Dox concentration. The ability (Dox)-loaded DC Bead LUMI™ to be visualized in vivo was demonstrated by the administration of into hepatic arteries of a VX2 tumor-bearing rabbit under fluoroscopy, followed by subsequent CT imaging.
Introduction
Drug-eluting Bead (DEB) technology has now been available to the physician for more than a decade and allows the delivery of the chemotherapy and the embolization agent concurrently [1, 2] , simplifying the transarterial chemoembolization (TACE) procedure and allowing for a greater degree of standardization of the treatment (DEB-TACE) [3, 4] . Moreover, the controlled and sustained delivery of the drug offers an improved safety profile over conventional TACE due to lowered systemic levels of drug [5, 6] . The DEBs are mixed with soluble contrast at the appropriate dilution and to provide a homogeneous suspension that can be delivered via syringe through the narrow lumen of the microcatheter without occluding it. The contrast-bead suspension flows into the blood stream and the DEBs are carried by the arterial flow into the tumor vessels until they physically block by virtue of their size. DEBs are provided in a range of sizes for this reason, to allow the physician to select the bead depending upon the vessel anatomy to be embolized. When the first DEB was first introduced into clinical practice (DC Bead™), the most common size range of product selected for treating hepatocellular carcinoma (HCC) was 500-700 μm based upon the sizes of embolic agent that were routinely used at the time for cTACE [6, 7] . As clinicians have become more experienced with the product and confident in its performance, it is now more usual to treat with 100-300 μm DC Bead™, or if so desired, to achieve even more distal penetration by using DC BeadM1™ (70-150 μm) [8] or this in combination with 100-300 μm DC Bead™ [9] . Smaller beads loaded with irinotecan are recommended when treating colorectal cancer metastases to the liver due to their relative hypovascular nature [10, 11] .
Whichever the technique employed in the treatment, the Interventional Radiologist (IR) relies upon monitoring of blood flow reduction by virtue of the contrast media mixed with the beads, in order to judge when sufficient embolic has been delivered to reach the intended end-point. As the beads themselves are not radiodense, there is no way of locating their exact location; but instead, it has become commonplace to use the phenomenon of trapped soluble contrast retention as a surrogate for assessing successful devascularization [12, 13] . This requires a CT scan to be performed within the first 6 h of bead administration, as the process of devitalising the tumor means that some of the contrast agent that has been delivered in conjunction with the beads becomes resident in the embolized tissue and its elimination by the usual wash-out mechanisms is retarded. With the adoption of intraprocedural cone-beam CT becoming more widespread, this practice is helping to guide the IR and ensure a greater extent of technical success in the DEB-TACE procedure. Despite this, there remains a desire by the IR to see the DEBs themselves, to provide intraprocedural feedback on treated locations and help avoid off-target embolization and to allow for better evaluation of tumor coverage.
We have previously reported on the use of a lyophilized version of DC Bead™ that can be loaded with Lipiodol® and drug in order to attain a radiopaque DEB [14] [15] [16] . This enabled the demonstration of the utility of such a product and provided the proof of concept that bead concentration could be correlated to attenuation to provide a quantitative measure of iodine levels in the bead, and subsequently, that the degree of radiopacity could be correlated to drug concentration (in this case doxorubicin (Dox)) [15] . This finding provides a tantalizing insight into a potential future innovation for radiopaque (RO) DEBs, for which if drug diffusion around the beads can be mapped on a spatial and temporal basis, the concept of DEB dosimetry and dose-painting could become a real prospect to help better quantify and tailor drug delivery to tumors. To this end, we have been developing a more convenient version of a radiopaque DC Bead™ that has intrinsic radiopacity to avoid the need to undertake any contrast loading process. Our initial approach was to couple triiodobenzoyl groups (the basis of most commercial iodinated contrast media) to the preformed beads by various linking groups [17] . This posed some technical challenges, as the presence of such hydrophobic moieties within the hydrogel structure of DC Bead™ resulted in unusual behaviour that was deleterious to the bead properties. These issues were eventually overcome in order to arrive at a RO DEB that can be handled and administered as in normal clinical practice [18, 19] , has excellent drug elution properties and good levels of radiodensity to be usefully imaged under a range of different imaging modalities. Here we report on the characterization of this novel, intrinsically radiopaque DEB, DC Bead LUMI™.
Materials and methods

Bead synthesis
Preparation of 2,3,5-triiodobenzaldehyde
In a 50 mL three-necked round-bottomed flask fitted with a thermometer, a nitrogen bubbler and an air-tight seal, (10.2 g, 0.021 mol) of 2,4,5-triiodobenzyl alcohol (Sigma Aldrich, Poole, UK) was dissolved in 100 mL of anhydrous DMSO (Romil, Cambridge, UK) under a nitrogen blanket and stirring conditions. Then, 1.0 mol equivalent of propane phosphonic acid anhydride (Sigma Aldrich, Poole, UK), (T3P), (50% solution in ethylacetate) was added drop by drop over 5 min at 22°C-25°C. The reaction solution was stirred at room temperature and monitored by high performance liquid chromatography (HPLC). The conversion finished after 240 min (scheme 1). The yellow solution was poured into 100 mL of deionised water while stirring, yielding a white precipitate which was filtered, washed with the mother liquors and 50 mL of deionised water. The cake was slurried in 50 mL of ethylacetate (Romil, Cambridge, UK), filtered and washed with 50 mL of water again, dried in vacuo at 40°C for 20 h to yield (7.7 g, 75.8%) of a white solid. The structure and purity were confirmed by NMR analysis and HPLC.
Preparation of dried PVA hydrogel beads
The beads were produced using a PVA-based macromer (150 g, equivalent to 3.41 mol of CH 2 CH 2 OH units) that was synthesized by the acid-catalyzed (HCl, pH 1-2) reaction of N-acryloylaminoacetaldehyde dimethylacetal (0.104 mmol/g of PVA, 2.49 g) (NAAADA, Ciba Vision GmbH, Großwallstadt, Germany) with the 1,3 diol units on a 67 kDaL PVA backbone (Mowiol® 8-88, Sigma Aldrich, Poole, UK) to form a stable cyclic acetal structures with pendent reactive acrylamide groups. The macromer solution 21% w/w (400 g) was mixed with 2-acrylamido-2-methylpropanesulfonate sodium salt (140 g, 0.61 mol) (AMPS, Sigma Aldrich, Poole, UK) and potassium persulfate(5.22 g, 0.019 mol) (one half of the initiator redox couple) in aqueous media stabilized by cellulose acetate butyrate to prevent coagulation and suspended in butyl acetate with stirring. The mixture was stirred (speed of stirring being used to control the droplet size) and heated to 60°C and then tetramethylethylenediamine (6.4 mL, 0.055 mol) (TMEDA, the other component of the redox couple) was added to the oil phase, where upon free-radical copolymerization was initiated and a water-swollen cross-linked network formed (Scheme 2). The swollen beads were washed with high purity water and then extracted with two sequential boil washes in buffered saline to remove residuals. The beads were then mechanically separated into 40-90 μm, 70-150 μm or 100-300 μm size fractions using a sieve stack with copious washing using purified water. After sieving the beads were dried by washing in acetone and drying in an oven at 40°C overnight to form a free-flowing powder, approximately 200 g total yield.
2.1.3. General preparation of radiopaque beads from 2,3,5-triiodobenzaldehyde and preformed cross-linked PVA hydrogel beads
The dried PVA hydrogel beads (4 g) were placed in dimethyl sulfoxide (DMSO) and reacted with 2,3,5-triiodobenzaldehyde (6.6 g, 0.14 mol) in an acid-catalyzed (methane sulfonic acid) reaction under nitrogen with stirring, to form stable cyclic acetal linkages with pendent triiodobenzoyl moieties (scheme 3). Consumption of the aldehyde was monitored using HPLC and once complete, the reaction was cooled to room temperature and filtered. The cake of beads was washed thoroughly with copious amounts of DMSO and then water, until free of unreacted aldehyde as determined by HPLC.
Evaluation of bead physicomechanical properties
Sizing and optical microscopy
Bead size was determined by forming a monolayer of beads within a petri dish and images acquired at ×10 magnification using an Olympus BX50 microscope equipped with a ColorView III camera. Sizing was performed manually on population of at least 200 microspheres randomly throughout the dish using the sizing tool provided in the AnalySIS software package (Soft Imaging Systems GmbH, Berlin, Germany).
Energy dispersive X-ray analysis (EDAX) micro-mapping of bead elemental composition
Beads were embedded in PVA gel (FSC 22) and sectioned using a cryomicrotome (Leica CM1860) to 10 μm thick slices. The sample cross-sections were sputtered with gold and placed in a Hitachi 5-3500N scanning electron microscope fitted with an Oxford instruments X-MaxN 50 Energy Dispersive X-ray Spectroscope. Elemental mapping was performed and plotted as a function of elemental abundance along a survey line profile across the bead diameter.
Measurement of bead elastic modulus
The modulus of the beads was measured to provide a guide as to their deformability. The method used was based on that recently reported in detail elsewhere [18] in which the elastic modulus was calculated using a UMIS 2000 nanoindentation system (CSIRO Instruments, Lindfield NSW, Australia) operated by IBIS software (Force range 0.01 mN-45 mN; displacement range 1 nm-100 μm). Individual beads of known diameter were compressed under saline (unloaded) or deionised water (drug-loaded) at a constant strain rate (~1-2%/s) generating a force displacement curve that was analysed for peak modulus values (N = 20).
Determination of bead density
Bead density was determined by using Eppendorf tubes containing a plastic insert with a 5 μm pore size at the bottom of the insert. The insert was wetted with saline, centrifuged at 1200g for 1 min and the weight of wet insert recorded. Beads were added to the insert and the centrifugation and weighing steps were repeated. The density of wet beads was determined by measurement of the displacement of saline from a graduated cylinder to obtain the bead volume and dividing through by the mass of beads (mass/volume, N = 3).
Zeta potential measurements
The zeta potential of beads was analysed at Reading Scientific Services Ltd. (Reading, UK) using a Malvern Zetasizer ZSP. Disposable polycarbonate folded capillary cells were used for the analysis. The cells were verified each day before use using a latex zeta potential transfer standard supplied by Malvern. Prior to analysis, samples were incubated in a 25°C water bath for a minimum of 30 min. A glass Pasteur pipette was used to transfer sample into the folded capillary cell. The filling was carried out as quickly as possible to limit sedimentation of the sample before measurement. Once filled, any air bubbles present were removed by gently tapping the cell on the bench. The cell was then inserted into the Zetasizer and the measurement commenced at 25°C. constant = 79.0) in order to maintain a durable suspension of the beads in the fluid. Each sample was filled into the cell and measured according to the above procedure three times to gain an indication of repeatability. The beads used in the assessment were the 70-150 μm size range of DC Bead™ and DC bead LUMI™, with and without doxorubicin loaded at 37.5 mg/mL.
Bead suspension, handling and catheter delivery assessments
Bead suspendability and catheter delivery properties were evaluated in a syringe-based model to replicate the clinical practice as previously described by us in detail. Non-ionic contrast agents evaluated included iohexol (Omnipaque 350, GE Healthcare), iodixanol (Visipaque 320, GE), iomeprol (Iomeron 300 and 400, Bracco) and iopamidol (Niopam 300, Bracco) together with a range of bead sizes. Micro-catheters evaluated included 2.0 Fr Progreat® (Terumo, Somerset, NJ) a 2.4 Fr Renegade® (Boston Scientific Corp.) and 4.0 Fr Radiofocus Glidecath® (Terumo).
Bead imaging evaluations 2.3.1. micro-Computed Tomography (μ-CT) analysis
Homogeneous agarose bead phantoms were prepared as detailed previously [16] . These were analysed with μ-CT (Reading Scientific Services Ltd., Reading, UK) using a Bruker SkyScan 1172 μ-CT scanner (Kontich, Belgium) using a voltage of 64 kV, a current of 155 μA and an aluminium filter (500 μm). The samples were then reconstructed using Nrecon and calibrated against a volume of interest of air and purified water to yield Hounsfield Units (HU) for individual beads (N = 6).
Fluoroscopy assessment of line phantoms
Line phantoms of beads were prepared as described previously by creating a 2 mm diameter lumen in a tube filled with agar gel and filling this with a concentrated bead slurry by concomitant injection of the slurry and withdrawal of the needle along the lumen tract. Fluoroscopic evaluation was performed using a Philips AlluraClarity (R8.1) system (Philips, Best, The Netherlands). The measurements were performed by positioning the line phantoms on Poly(methyl methacrylate) (PMMA) slabs of either 19.5 cm or 28.5 cm thickness to model patient absorption (typical and high BMI surrogates), using clinically-relevant imaging and geometry settings using 2 D protocols. The SID was fixed at 110 cm and the imaging session was performed using a 27 cm detector size. The following (AlluraClarity) acquisition and image processing settings were then used: (i) Vascular Fluoroscopy (low/ medium/normal); (ii) Cardiology CINE (LCA low/boost); (iii) Single shot (abdomen/neuro). Essentially, these settings represent low, medium and high levels of radiation exposure, with better images expected the higher the exposure. Only standard contrast and brightness settings were adjusted to enhance visibility. Since a static phantom was used, a single image of each run was selected for the end-report.
CT evaluation of homogeneous bead phantoms and drug extraction
The distribution of conjugated iodine contrast agent within the bead agarose phantoms was imaged on a clinical 256 Slice CT (Philips, Andover, MA) to determine the overall attenuation. The following settings: 465 mAs tube current, 120 kV tube voltage, 2 mm thickness, 0.5 mm overlap were used. The average attenuation of a 92.4 mm 2 cylindrical region along the phantom was selected and measured in grey scale using OsiriX (V.5.02 64-bit) and later converted into HU from a two point regression curve for water and air. Dox content was calculated based on the total bead volume in the phantom and amount of Doxloaded (37.5 mg/mL).
Imaging of beads in a VX2 tumor model
All animal-related procedures were approved and carried out under the guidelines of the National Institutes of Health (NIH) Animal Care and Use Committee. VX2 tumors were established similarly to previous reports [20] [21] [22] [23] . Briefly, a single cell suspension of VX2 cells was inoculated into the hindlimb of a Female New Zealand White rabbit (donor). Intrahepatic tumors were established in rabbits weighing 3-3.5 kg by percutaneous injection of tumor fragments from the donor into the left lobe of the liver under ultrasound guidance. Tumor growth was monitored using ultrasound until a tumor diameter of 1.5 cm was achieved.
For TACE, rabbits were anesthetized and the femoral artery was surgically exposed and cannulated using a 3-F vascular sheath (Cook, Inc., Bloomington, Indiana). Subsequent selective catheterization of the proper hepatic artery was achieved via a 2.4-F microcatheter (Progreat; Terumo Medical Corporation, Somerset, NJ) under fluoroscopic guidance (Allura Xper FD20; Philips, Andover, MA). Radiopaque beads containing 37.5 mg of doxorubicin per milliliter of packed wet beads were suspended in Omnipaque 350 contrast media at a dilution of 1:20 and injected until flow stasis. Rabbits were euthanized (euthosol 1 mL/10 lb; Virbac Animal Health, Fort Worth, TX) after 1 h to allow for soluble contrast wash-out and a CT scan (Brilliance CT-16 slice; Philips, Andover, MA) was acquired post mortem with 0.8-mm slice thickness and 0.4 mm overlap. These images were compared to those obtained from a patient treated with the same sized beads in the first human experience of this product [24] .
Bead drug loading and elution evaluations 2.4.1. Drug loading evaluations
Doxorubicin hydrochloride (Dox, Hisun, China), and irinotecan hydrochloride (Iri, Scianopharm, China) were obtained as pure powders (N 99% purity) and dissolved in deionised water at the desired concentration to obtain stock solutions for bead loading experiments. Samples of the beads under study were loaded with a target dose of the desired drug. The bead samples were first transferred from their product vials to 10 mL syringes using a needle via a measuring cylinder. 1 mL of beads was measured into each syringe. As much residual packing solution was removed as possible from the beads by leaving them to settle in the syringe (placed vertically), and by pushing out the packing solution from the top of the syringe using the plunger. Drug loading was then initiated by the addition of the drug solution at the desired concentration. The actual amount to be added was calculated based on the measured concentration of the drug loading solutions and pipetted accurately into a vial. The drug solution was then transferred to the syringes containing bead sample. Note that in some countries, powdered Dox is difficult to obtain and so hospital pharmacies use pre-formulated Dox solutions that have a concentration of 2 mg/mL. Loading studies were also therefore conducted using Dox solutions made at this concentration, as less concentrated drug solutions are known to take longer to load. Upon the addition of drug loading solution into the syringes a stop watch was started, the syringes closed with a cap and placed in one of the following conditions:
• Syringes were secured on a plate shaker set at 720 rpm at ambient.
• Syringes were agitated every 5 min by rolling the syringe between the hands 10 times followed by inverting the syringe 10 times at ambient.
• At ambient temperature, syringes were agitated every 5 min by rolling the syringe between two hands 10 times followed by inverting the syringe 10 times. After first 30 min sample collection.
• Syringes were placed in a fridge (2-8°C) with restricted movement.
Aliquots of samples were taken under static condition without shaking.
At time points of 10, 20, 30, 45, 60, 90, 120, 240, 360 and 1440 min after the initial addition of the drug solution a 10 μL aliquot of the depleted drug solution was withdrawn from the syringes of beads for Dox or Iri loading determination. More or less time points were taken depending on the speed of drug loading during test. The depleted drug solution aliquots were diluted with deionised water and then measured for drug concentration against standards (solutions of drug prepared in duplicate with a known concentration, measured by UV spectrophotometry at 483 nm for Dox and 369 nm for Iri using an Agilent Technologies UV spectrophotometer and calculated to agree in terms of weight of drug to UV absorbance). The amount of drug loaded into the beads at each time point was then calculated based on the concentration of drug initially added to the syringes of beads and the amount measured in the aliquots of depleted solution. Loading profiles were then created.
Drug elution evaluations
Drug-loaded bead samples prepared in Section 2.4.1 were tested alongside DC Bead™ controls. The open loop flow through system used to perform the elution studies consisted of PBS stock, peristaltic pump, flow through elution cell, water bath with temperature control unit, UV spectrophotometer, and waste collection [25] . The drug-loaded beads were introduced between two SeFar filter membrane (pore size 27 μm) in the elution cell, and the distance between the two filter membranes was 6-7 mm. Deionised water was used here as packing medium to avoid pre-drug leaching, and during bead packing, air bubbles were carefully avoided from being introduced into the system. Further measures were adapted later by using preheated solution and an air trap to exclude air from entering the elution cell. After assembling the system, PBS was pumped through the elution cell at 37°C and using a speed around 1.3-1.6 mL/min, which was selected to balance the elution time and PBS consumption by considering drug diffusion in the beads as rate control step. The eluted drug was passed through UV spectrophotometer, and monitored at 483 nm for Dox and 369 nm for Iri, respectively. Due to the high extinction coefficient of Iri and its relatively high initial rate of elution, eluted Iri detected above absorbance of 2 was collected through a Lambda fraction collector at 15 min intervals per sample until the absorbance signal dropped below 2 again. The data collected were processed using Excel. Firstly the absorbance data were converted to concentration by comparing to the standard solution. Then the area under curve (AUC) and cumulative amount of drug eluted were calculated against time in minutes. The average elution curve was drawn by averaging three replicated measurement, and error bars applied from the standard deviation calculation.
Results and discussion
Bead synthesis
We have previously demonstrated the utility of radiopaque beads for use in transarterial chemoembolization, by use of a modified version of the commercial DC Bead™ product which was prepared in lyophilised form in order that it could be mixed with, and absorb into its structure, the oily contrast agent Lipiodol™ [14] [15] [16] . Although a useful tool for proof of principle, the preparation process was not conducive for everyday clinical use and alternative approaches were sought in which the radiopacity could be provided as an inherent characteristic of the beads. We recently reported upon a strategy for coupling 2,3,5-triiodobenzyl units to preformed PVA hydrogel beads by activating the bead with 1,1′-carbonyldiimidazole and conjugating with 2,3,5-triiodobenzoic acid and 1,3 diaminopropane as a spacer to alleviate steric hindrance [17] . While this resulted in beads with excellent radiopacity, the flexibility of the appended moieties allowed for structural reorganisation during sterilisation that negatively compromised the ability of the beads to load drugs into their structure.
The subsequent process we have developed to overcome this shortcoming involves the coupling 2,3,5-triiodobenzoyl moieties directly to 1,3 diol units of a preformed PVA hydrogel beads and is remarkably efficient in nature. Given the hydrogel beads are highly swollen in DMSO, the TBA is able to diffuse into the swollen matrix and react evenly throughout the hydrogel structure; although care must be taken to control the rate of reaction to avoid preferential surface coupling and a consequent "halo effect" on imaging. The uniformity of coupling within single beads is demonstrated both by energy dispersive X-ray analysis (EDAX) of physically cross-sectioned beads and by micro-computed tomography (μ-CT) imaging analysis of whole beads embedded in gelatin phantoms shown in Section 3.3 ( Figs. 1 and 5 ). The latter also confirmed consistent reaction within a larger sample of beads measured from multiple batches (Fig. 6 ). We have recently described in detail the optimization of the degree of TBA coupling, providing the balance between increase in bead density and subsequent challenges in bead handling and administration versus levels of radiopacity and extent of bead visibility under various imaging modalities both in vitro and in vivo. Here we expand upon this work using the optimized level of~150 mg iodine/mL sedimented beads to encompass drug interactions and their impact on bead properties. 
Bead properties
The resultant beads (DC Bead LUMI™) are a pale golden color due to the iodine presence, which means there is no need to add a color-tint with dye in order to visualize beads in suspension (Fig. 2) . This product can be steam sterilized, which results in a tightening of the structure and a decrease in the average diameter compared to the unmodified PVA hydrogel beads. Structural integrity is maintained, providing for smooth, round and robust beads, that can be mechanically sieved into desired size fractions. Moreover, the beads retain their ability to absorb and bind cationically-charged drugs such as Dox and Iri hydrochloride (Fig. 2) . When DC Bead LUMI™ are loaded with either Dox or Iri at the recommended maximum loading levels used for DC Bead™, there is no impactful change in the average size of the beads nor their settled volume, unlike DC Bead™ which experience a shrinkage in the average bead diameter of between 20 and 30% and a corresponding reduction in sedimented bead volume, depending upon drug type and concentration (Fig. 3) . , minimum and maximum range for three size ranges of DC Bead LUMI™ unloaded, loaded with 37.5 mg/mL Dox or loaded with 50 mg/mL Iri; inset (b) shows representation size distribution curves for unloaded and drug-loaded 70-150 μm DC Bead™ LUMI. ANOVA showed a statistically significant difference between beads sizes (p b 0.0001) as anticipated, but also within each size group comparing unloaded, Dox and Iri (although the latter is not impactful on sedimented bead volume as the difference is driven by the large number of data points and the difference in the skewness of each of the distribution curves since they are not normally distributed populations).
Zeta potential measurement is often performed to determine the presence and extent of surface charge on a particle. The measurement of the zeta potential for the beads in this study needed to be carried out in different media in order to maintain a durable suspension sufficient for the measurement to be taken. This introduces some difficulty in directly comparing these values, as the zeta potential is a measure of the charge a particle acquires in a particular medium and sample preparation should aim to preserve the existing state of the particle surface wherever possible [26] . The zeta potential for DC Bead™ was measured in saline, which had a much higher conductivity and ionic strength than the samples measured in contrast agent or mixtures with saline (Table 1) . Ionic strength influences zeta potential through specific or non-specific interactions of the ions in the medium with charged species on the particle surface. In specific ion interactions, ions bind directly to charged species on the particle surface and thus impact on the isoelectric point of the particle. In non-specific interactions, the ions do not directly bind with the charged species but their presence in the medium influences the measured zeta potential, for example through a particle-particle charge screening effect [27] , it is not immediately apparent which phenomenon will have a dominant effect. Table 1 shows that zeta potential values for unloaded DC Bead™, DC Bead™ loaded with Dox, DC Bead LUMI™ and DC Bead LUMI™ loaded with Dox. The zeta potential for DC Bead™ decreases slightly when measured in undiluted contrast agent compared to saline (−10.2 mV vs − 15.2 mV respectively) but both of these values are consistent with previously reported measurements that were made in a pure water medium (~−16 mV, [28] ). DC Bead LUMI™ has a higher zeta potential, suggesting more negatively charged groups are expressed at the bead surface. This may be due to the presence of the hydrophobic triiodobenzyl groups in the structure, which will organise themselves into hydrophobic domains in the interior of the bead in the presence of water, favouring expression of the sulfonate groups at the surface. When Dox is loaded into either DC Bead™ or DC bead LUMI™, the zeta potential is reduced by neutralization of the some of the negative charge at the bead surface due to the ionic interactions with the positively charged drug. For both bead types however, the overall surface charge remains negative. This may help explain why although DC Bead LUMI™ contains a significant proportion of hydrophobic component in its structure, when prepared and delivered in aqueous media, the charged surface predominates and acts to prevent the beads from interacting with themselves or other surfaces with which they contact.
The addition of the radiopaque groups to the DC Bead LUMI™ hydrogel structure also increases the bead density to 1.307 g/cm 3 compared to 1.031 g/cm 3 for DC Bead™ ( Table 2 ). The density increases slightly further for both beads when loaded with either doxorubicin or irinotecan, as water is displaced from the hydrogel structure and is replaced by drug. This increase in solids content means that DC Bead LUMI™ is two orders of magnitude stiffer to compress than DC Bead™ (Table 2) , although this is unlikely to impact on the depth of penetration into vessels as we have previously demonstrated with bench penetration testing [18] . Likewise, administration through microcatheters remains unproblematic with these sizes of beads (Table 3) , provided the appropriate bead dilution is maintained. Suspension in undiluted contrast agent is now possible with the increase in density, further enhancing intra-procedural visibility during administration of the beads (Table 4) . Bead suspensions in Iomeprol 400, whether unloaded or drug loaded were very durable (Table 5) , although drug loading the beads in this case caused them to settle more quickly (albeit still relatively slowly compared to other contrast agents). The opposite was true for bead suspensions in Iodixanol 320, where very long times in suspension were observed for Dox-loaded beads in this contrast agent. In general, Iomperol 400, Iohexol 350 and Iodixanol 350 are favoured for unloaded and Dox-loaded DC Bead LUMI™, whereas Iodixanol 350 would not be suitable for Iri-loaded DC Bead LUMI™, as this contract agent is formulated with high levels of ions that can cause a premature burst release of the Iri when first mixed.
Bead imaging performance
Micro-CT confirmed the observation made with EDAX that the iodine moieties are uniformly distributed throughout the bead interior. Furthermore, it also showed that loading of either Dox or Iri does not ((−) signifies that beads could not be suspended for long enough to take a measurement). Table 3 Microcatheter deliverability of DC Bead LUMI™ (unloaded, loaded with 37.5 mg/mL Dox or 50 mg/mL Iri). affect the distribution of iodine within the bead structure (Fig. 4) , nor the overall level of radiopacity (Table 6) . Neither is the level of radiopacity majorly influenced by the bead size within this overall range of 40-300 μm.
Fluoroscopic evaluation of line phantoms demonstrated that the imaging visibility was independent of bead size and drug loading, with the extremes of the beads size ranges (40-90 μm and 100-300 μm), either unloaded or loaded with Dox at 37.5 mg/mL, were equally visible under all of the imaging modalities employed. The phantom lines were clearly visible using 'normal' fluoroscopy for a PMMA thickness of 19.5 cm, while a Cardio CINE dose level was required to achieve adequate visibility for a PMMA thickness of 28.5 cm. Visibility was satisfactory however, for all conditions using Single-Shot (Fig. 5) .
Imaging of phantoms containing a range of bead suspension densities was performed using 70-150 μm beads loaded with 37.5 mg/mL doxorubicin in order to provide for a correlation between the attenuation of the beads and drug concentration. Fig. 6 demonstrates that there is a direct relationship between the radiopacity of the beads and the doxorubicin concentration within the sample. The intriguing question arises, as to whether in the future it will be possible to predict the concentration of drug delivered to various parts of the tumor from the imaging distribution pattern (so called "dose-painting") and hence identify areas of under-treatment that can be addressed by additional loco-regional approaches to achieve a better overall tumor response. 
Table 6
Effect of drug loading and bead size on radiopacity of DC Bead LUMI™ (Hounsfield units, n = 3).
DC Bead LUMI™ Bead size (μm)
Radiopacity by μ-CT (HU, distilled water = 0, air = −1000) This is the subject of a follow-up study [29] which we will report more fully in due course. For the current study, however, it was important to demonstrate that Dox-loaded DC Bead LUMI™ could be vizualised in vivo.
Feasibility was demonstrated using Dox-loaded DC Bead LUMI™ (70-150 μm, 37.5 mg/mL) administered transcatheter into the main hepatic artery of a rabbit bearing a hypervascular VX2 tumor under standard fluoroscopic guidance. The DC Bead LUMI™ could not be observed flowing from the microcatheter as they were suspended in contrast agent. As the contrast flowed along the vessels it was cleared from view after several heart beats and careful observation of the fluoroscopic image, particularly in single shot high resolution mode, showed the beads accumulating in the vessels as a series of dark lines. Embolization was complete once stasis or near stasis had been achieved and the rabbit left for 1 h to allow soluble contrast to wash away before sacrifice in order to obtain a multidetector computed tomography (MDCT) image without breathing artefacts (Fig. 7(A + B) ). The images in Fig. 7(A + B) clearly show for the first time, the presence of Dox-loaded DC Bead LUMI™ in the arterial vasculature surrounding the tumor. The tumor vessels are relatively small in this model and few beads penetrated within the tumor interior, as seen previously with this tumor model [18] ; although the area of the tumor was seen not to enhance to the same degree as the surrounding parenchyma, suggesting its arterial supply had been successfully devitalized. As expected in this model, because the procedure was performed to maximise the amount of beads delivered into the liver, filling of both tumor-feeding and non-target vessels was clearly evident from the 3D reconstruction in Fig. 7(B) . Fortuitously, the first images of a patient with hepatocellular carcinoma treated with DC Bead LUMI™ became available to allow a comparison of what is seen in the rabbit model versus the human situation with a hypervascular tumor (Fig. 7(C) ). The arterial network in the human tumor is much larger than the rabbit and the majority of the beads are seen to penetrate deeper into the tumor mass highlighting its hypervascularity, with some minor non-target vessels visible at the periphery of the tumor. This highlights one of the short-comings of the rabbit VX2 tumor model, as although it may have a hypervascular structure, those vessels are much smaller than in those human tumors normally treated with DEB-TACE and hence bead distribution can be expected to be much more peripheral in nature.
DC Bead LUMI™ drug loading and elution characteristics
In order to effectively characterize DEB products it is important to understand the rate and extent of the elution of drug from the beads in vivo. In vitro test methods with strong correlation to in vivo behaviour are critical to the development of DEBs, allowing predictive investigations into changes in material, product format and drug types for instance, to deliver efficacious and predictable clinical solutions [30, 31] .
There are a number of reported methods in the literature for evaluating drug release in vitro, however, few are representative of the in vivo environment experienced when beads are implanted within blood vessels. The USP II dissolution method is more suited to oral release formulations and over-estimates the rate of drug release from DEBs and can misinterpret the extent of drug release [30] . Amyot et al. developed a T-Apparatus that combines both diffusion and convection parameters of drug elution to better mimic distal elimination of drug from open vessels distant from the site of embolization [32] . The USP IV method is finding more widespread use but still does not offer a representative mode of embolization as there is a continuous flow of elution media around the DEB and can be unsuitable for products in development with more challenging physical properties [33] . In order to reflect the actual bead elution properties under embolized conditions and to overcome the aforementioned limitations, a prototype open loop flowthrough method was developed and characterized elsewhere in detail [25] . This method was set up to mimic the USP dissolution apparatus IV (USP IV) flow through mechanism, which included a flow through cell, medium storage tank, peristaltic pump and UV spectrometer. In the USP IV method, the elution medium is passed through a chamber containing dosage forms, and the released drug is measured by an in situ UV spectrometer. The new method has been modified by us to improve the correlation of in vitro drug elution from embolized beads to the conditions expected in in vivo. Preliminary testing of the prototype open loop method showed that the majority of the drug loaded into the beads could be eluted using this apparatus and PBS.
Drug loading characteristics
Several different loading conditions were investigated to examine their effect on rate of drug uptake into DC Bead LUMI™ from solutions prepared with powdered Dox. Static loading (without any agitation at all) was inefficient for Dox, with b 70% of the drug loaded in 2 h and 100% loading requiring over 30 h. Full loading could be achieved within 2 h if intermittent or constant agitation (e.g. on a plate shaker) was used. Dox uptake was dependent upon bead size in the order 40-90 μm N 70-150 μm N 100-300 μm and is a function of the increased surface area to volume ratio for smaller bead sizes as described previously ( Fig. 8(A) ). For the lower concentration Dox solutions (2 mg/mL) that represented the formulated solution available in many hospitals, loading experiments confirmed that complete loading of 37.5 mg/mL of Dox could be achieved in 3 h with constant agitation. The use of lower Dox target loadings or smaller bead size both increased the rate of loading to between 30 and 90 min (Fig. 8(B) ).
Iri uptake was more rapid, with even 95% loaded in 10 min under static conditions or 100% loaded by the first measurement at 10 min if conducted with some agitation. Again, smaller beads loaded Iri more quickly, although the rate of uptake in 40-90 μm and 70-150 μm beads could not be discerned by the first sampling time at 10 min ( Fig.  8(C) ). These data support the capability of DC Bead LUMI™ to be able to load both Dox and Iri in reasonable timeframes consistent with hospital pharmacy practice such that the product can be prepared in advance (typically the night before) prior to use in a DEB-TACE procedure.
Drug elution characteristics
Bead size range has very little impact on Dox release using this flowthrough model, with all beads sizes producing similar elution profiles ( Fig. 9(A + B) ), unlike the USP II method where rate of release increases with an increase surface area to volume ratio (decrease in bead size) [33] . This is because the beads form an effective embolic plug in all beads size cases, which controls the drug diffusion and limits the surface area effects observed for the classic USP II type dissolution tests where elution media surrounds and efficiently extracts the individual beads. The raw data are a little noisy for 500-700 μm DC Bead™ as these showing a 3D reconstruction of the distribution of beads around the area of the tumor (hatched arrow, area of decreased enhancement), within both tumor-feeding vessels and nontarget arteries in the liver; (C) a comparative axial CT image of a human patient with hepatocellular carcinoma (hatched arrow) in which the beads can be clearly seen mainly filling the arteries in the interior of the tumor mass and some minor non-target arteries at the periphery (yellow arrows) [24] . beads swell significantly as they elute, which interferes with the flow of the extraction media ( Fig. 9(A) ). Again, 100% of the Dox is released from the beads regardless of the size range evaluated. The increased hydrophobicity of the DC Bead LUMI™ hydrogel matrix means that beaddrug interactions are increased and elution of these species is retarded compared to DC Bead™. One could therefore expect to observe a decrease in the peak plasma concentration (C max ) for DC Bead LUMI compared to the equivalent sized DC Bead™. However, DC Bead™ size ranges between 70 and 150 μm up to 500-700 μm have been used in clinical practice [6] , and the overall profile of elution for the RO DEBs is within the elution envelope of that for the DC Bead™ product range ( Fig. 9(B) ). Given that human pharmacokinetic data has been generated for both the 70-150 μm [34] and 500-700 μm DC Bead™ products [6] , and both have been proven to be safe and effective, it is anticipated that the radiopaque beads should therefore enjoy similar benefits. Similarly, it can be expected that the in vivo Dox elution into tissue from DC Bead LUMI™ will be at therapeutically meaningful levels for at least 30 days as demonstrated for DC Bead™ [35, 36] .
Iri elution from DC Bead LUMI™ was slightly slower and more sustained for an equivalent loading level compared to DC Bead™ (Time for 50% elution (t 50% ) being 23 and 28 min for 70-150 and 100-300 μm DC Bead™ respectively compared to 48 and 46 min for the same sizes of DC Bead LUMI™ respectively). The initial burst effect is also reduced (Fig. 10(A) ) as more clearly seen from the raw elution data, where there is a marked reduction in the initial spike in concentration (the so-called "in vitro C max ") when comparing DC Bead LUMI™ with DC Bead™. Again, this is due to the more hydrophobic, lower water-content polymer matrix having an impact on retarding the diffusion of the drug. The majority of the Iri, regardless of dose loading amount, was eluted from the bead matrix in the flowing elution model within 200 min, which is faster than Dox as there is no drugdrug interaction present for Iri ( Fig. 10(B) ). The remaining 5-10% took several hours to elute using this method (N2000 min) but all drug was released eventually. Again, bead size range has very little impact on Iri release using this flow-through model, with all beads sizes producing similar elution profiles, for the same reasons as Dox-loaded beads.
Conclusion
We have developed a straight-forward and efficient method of modifying PVA-AMPS hydrogel beads (DC Bead™) that are currently used in the clinic to treat liver malignancies, such that they are inherently radiopaque under various imaging modalities commonly employed in both their administration and clinical follow-up assessments (DC Bead LUMI ™). Although the chemical modification increases the density of the beads, we have shown them to be easily suspended, handled and administered through standard microcatheters and that their embolization potential remains unaltered. As the core chemistry of DC Bead LUMI™ is the same as DC Bead™, it interacts with drugs in the same manner; although its more hydrophobic matrix means that both Dox and Iri elution kinetics are slightly slower and more sustained compared to the equivalent size of DC Bead™ but within the elution window already validated within the clinic for the smallest and largest sizes of DC Bead™ [6, 35] . This product therefore builds upon the successful Fig. 9 . (A) Dox raw data elution profile for DC Bead™ (DC) and for DC Bead LUMI™ (LUMI) (both 37.5 mg/mL Dox) showing a small decrease in the in vitro C max ; (B) Cumulative elution data showing how Dox elution from DC Bead LUMI™ falls within the envelope of the clinically-studied sizes of DC Bead. Note that the entire drug is eventually eluted for both products but the study has been truncated to show the early time point data. heritage of DC Bead™ for use in the treatment of liver malignancies and provides a novel new property to enable intra-procedural and post-procedural feedback with standard imaging techniques; with real-time visualization of bead localization to help the physician optimize the treatment technique for improved clinical outcomes. The ability to see where the beads are going will enable the physician to more precisely target the area of treatment, identify areas of potential under-treatment and improve patient safety by detecting any off-target embolizationtogether with the benefits of the sustained localized release of chemotherapeutic agent.
